1. PD-L1 expression in non-small cell lung cancer: Correlations with genetic alterations.

    OncoImmunology 5(5):e1131379 (2016) PMID 27467949 PMCID PMC4910698

    Inhibition of the PD-1/PD-L1 pathway may induce anticancer immune responses in non-small cell lung cancer (NSCLC). Two PD-L1 immunohistochemistry (IHC) assays have been approved as companion diagnostic tests for therapeutic anti-PD-1 antibodies. However, many aspects of PD-L1 prevalence and asso...
  2. Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial.

    The Lancet Oncology 17(4):452 (2016) PMID 26973324

    ALK-rearranged non-small-cell lung cancer (NSCLC) is sensitive to ALK tyrosine kinase inhibitors (ALK inhibitors) such as crizotinib, but resistance invariably develops, often with progression in the brain. Ceritinib is a more potent ALK inhibitor than crizotinib in vitro, crosses the blood-brai...
  3. NOTCH, ASCL1, p53 and RB alterations define an alternative pathway driving neuroendocrine and small cell lung carcinomas.

    International Journal of Cancer 138(4):927 (2016) PMID 26340530 PMCID PMC4832386

    Small cell lung cancers (SCLCs) and extrapulmonary small cell cancers (SCCs) are very aggressive tumors arising de novo as primary small cell cancer with characteristic genetic lesions in RB1 and TP53. Based on murine models, neuroendocrine stem cells of the terminal bronchioli have been postula...
  4. Impact of PET/CT image reconstruction methods and liver uptake normalization strategies on quantitative image analysis.

    European Journal of Nuclear Medicine and Molecu... 43(2):249 (2016) PMID 26280981

    In oncological imaging using PET/CT, the standardized uptake value has become the most common parameter used to measure tracer accumulation. The aim of this analysis was to evaluate ultra high definition (UHD) and ordered subset expectation maximization (OSEM) PET/CT reconstructions for their po...
  5. Clinicopathological Characteristics of RET Rearranged Lung Cancer in European Patients.

    Journal of Thoracic Oncology 11(1):122 (2016) PMID 26762747

    Rearrangements of RET are rare oncogenic events in patients with non-small cell lung cancer (NSCLC). While the characterization of Asian patients suggests a predominance of nonsmokers of young age in this genetically defined lung cancer subgroup, little is known about the characteristics of non-...
  6. Developments in oncological positron emission tomography/computed tomography assessment.

    Journal of thoracic disease 7(12):E637 (2015) PMID 26793379 PMCID PMC4703688

  7. Implementing amplicon-based next generation sequencing in the diagnosis of small cell lung carcinoma metastases.

    Experimental and Molecular Pathology 99(3):682 (2015) PMID 26546837

    Small cell lung carcinoma (SCLC) is the most aggressive entity of lung cancer. Rapid cancer progression and early formation of systemic metastases drive the deadly outcome of SCLC. Recent advances in identifying oncogenes by cancer whole genome sequencing improved the understanding of SCLC carci...
  8. A Modeling and Simulation Framework for Adverse Events in Erlotinib-Treated Non-Small-Cell Lung Cancer Patients.

    AAPS Journal 17(6):1483 (2015) PMID 26286677 PMCID PMC4627460

    Treatment with erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor used for treating non-small-cell lung cancer (NSCLC) and other cancers, is frequently associated with adverse events (AE). We present a modeling and simulation framework for the most common erlotinib-induced ...
  9. A Synergistic Interaction between Chk1- and MK2 Inhibitors in KRAS-Mutant Cancer

    Cell 162(5):1169 (2015)

  10. Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations.

    New England Journal of Medicine 373(8):726 (2015) PMID 26287849 PMCID PMC4971773

    BRAF V600 mutations occur in various nonmelanoma cancers. We undertook a histology-independent phase 2 "basket" study of vemurafenib in BRAF V600 mutation-positive nonmelanoma cancers. We enrolled patients in six prespecified cancer cohorts; patients with all other tumor types were enrolled in a...
  11. Comprehensive genomic profiles of small cell lung cancer.
    Julie George, Jing Shan Lim, Se Jin Jang, Yupeng Cun, Luka Ozretić, Gu Kong, Frauke Leenders, Xin Lu, Lynnette Fernández-Cuesta, Graziella Bosco, Christian Müller, Ilona Dahmen, Nadine S Jahchan, Kwon-Sik Park, Dian Yang, Anthony N Karnezis, Dedeepya Vaka, Angela Torres, Maia Segura Wang, Jan O Korbel, Roopika Menon, Sung-Min Chun, Deokhoon Kim, Matt Wilkerson, Neil Hayes, David Engelmann, Brigitte Pützer, Marc Bos, Sebastian Michels, Ignacija Vlasic, Danila Seidel, Berit Pinther, Philipp Schaub, Christian Becker, Janine Altmüller, Jun Yokota, Takashi Kohno, Reika Iwakawa, Koji Tsuta, Masayuki Noguchi, Thomas Muley, Hans Hoffmann, Philipp A Schnabel, Iver Petersen, Yuan Chen, Alex Soltermann, Verena Tischler, Chang-min Choi, Yong-Hee Kim, Pierre Massion, Yong Zou, Dragana Jovanovic, Milica Kontic, Gavin M Wright, Prudence A Russell, Benjamin Solomon, Ina Koch, Michael Lindner, Lucia A Muscarella, Annamaria la Torre, John K Field, Marko Jakopovic, Jelena Knezevic, Esmeralda Castaños-Vélez, Luca Roz, Ugo Pastorino, Odd-Terje Brustugun, Marius Lund-Iversen, Erik Thunnissen, Jens Köhler, Martin Schuler, Johan Botling, Martin Sandelin, Montserrat Sanchez-Cespedes, Helga B Salvesen, Viktor Achter, Ulrich Lang, Magdalena Bogus, Peter M Schneider, Thomas Zander, Sascha Ansén, Michael Hallek, Jürgen Wolf, Martin Vingron, Yasushi Yatabe, William D Travis, Peter Nürnberg, Christian Reinhardt, Sven Perner, Lukas Heukamp, Reinhard Büttner, Stefan A Haas, Elisabeth Brambilla, Martin Peifer, Julien Sage, and Roman K Thomas

    Nature 524(7563):47 (2015) PMID 26168399 PMCID PMC4861069

    We have sequenced the genomes of 110 small cell lung cancers (SCLC), one of the deadliest human cancers. In nearly all the tumours analysed we found bi-allelic inactivation of TP53 and RB1, sometimes by complex genomic rearrangements. Two tumours with wild-type RB1 had evidence of chromothripsis...
  12. A Synergistic Interaction between Chk1- and MK2 Inhibitors in KRAS-Mutant Cancer.

    Cell 162(1):146 (2015) PMID 26140595

    KRAS is one of the most frequently mutated oncogenes in human cancer. Despite substantial efforts, no clinically applicable strategy has yet been developed to effectively treat KRAS-mutant tumors. Here, we perform a cell-line-based screen and identify strong synergistic interactions between cell...
  13. Implementation of Amplicon Parallel Sequencing Leads to Improvement of Diagnosis and Therapy of Lung Cancer Patients.

    Journal of Thoracic Oncology 10(7):1049 (2015) PMID 26102443

    The Network Genomic Medicine Lung Cancer was set up to rapidly translate scientific advances into early clinical trials of targeted therapies in lung cancer performing molecular analyses of more than 3500 patients annually. Because sequential analysis of the relevant driver mutations on fixated ...
  14. Spatial Tumor Heterogeneity in Lung Cancer with Acquired Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Resistance: Targeting High-Level MET-Amplification and EGFR T790M Mutation Occurring at Different Sites in the Same Patient.

    Journal of Thoracic Oncology 10(6):e40 (2015) PMID 26001148

  15. ROS1 rearrangements in lung adenocarcinoma: prognostic impact, therapeutic options and genetic variability.

    Oncotarget 6(12):10577 (2015) PMID 25868855 PMCID PMC4496376

    While recent data show that crizotinib is highly effective in patients with ROS1 rearrangement, few data is available about the prognostic impact, the predictive value for different treatments, and the genetic heterogeneity of ROS1-positive patients. 1137 patients with adenocarcinoma of the lung...
  16. Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: results from the EUROS1 cohort.

    Journal of Clinical Oncology 33(9):992 (2015) PMID 25667280

    Approximately 1% of lung adenocarcinomas are driven by oncogenic ROS1 rearrangement. Crizotinib is a potent inhibitor of both ROS1 and ALK kinase domains. In the absence of a prospective clinical trial in Europe, we conducted a retrospective study in centers that tested for ROS1 rearrangement. E...
  17. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial.

    The Lancet Oncology 16(3):257 (2015) PMID 25704439

    Patients with squamous non-small-cell lung cancer that is refractory to multiple treatments have poor outcomes. We assessed the activity of nivolumab, a fully human IgG4 PD-1 immune checkpoint inhibitor antibody, for patients with advanced, refractory, squamous non-small-cell lung cancer. We did...
  18. MET amplification status in therapy-naïve adeno- and squamous cell carcinomas of the lung.

    Clinical Cancer Research 21(4):907 (2015) PMID 25492085

    MET is a potential therapeutic target in lung cancer and both MET tyrosine kinase inhibitors and monoclonal antibodies have entered clinical trials. MET signaling can be activated by various mechanisms, including gene amplification. In this study, we aimed to investigate MET amplification status...
  19. Management of crizotinib therapy for ALK-rearranged non-small cell lung carcinoma: an expert consensus.

    Lung Cancer 87(2):89 (2015) PMID 25576294

    Within 4 years of the discovery of anaplastic lymphoma kinase (ALK) rearrangements in non-small cell lung cancer (NSCLC), the ALK inhibitor crizotinib gained US and European approval for the treatment of advanced ALK-positive NSCLC. This was due to the striking response data observed with crizot...
  20. PD-L1 expression in small cell neuroendocrine carcinomas.

    European Journal of Cancer 51(3):421 (2015) PMID 25582496

    Small cell lung cancer and extrapulmonary small cell carcinomas are the most aggressive type of neuroendocrine carcinomas. Clinical treatment relies on conventional chemotherapy and radiotherapy; relapses are frequent. The PD-1/PD-L1/PD-L2 pathway is a major target of anti-tumour immunotherapy. ...